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One Sentence Summary:  
MPLA combined with IFN reprograms tumor-associated macrophages and stimulates cytotoxic T cells to control 
metastatic breast and ovarian cancer. 
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Abstract 
Many cancers recruit monocytes/macrophages and polarize them into tumor-associated macrophages (TAMs). 
TAMs promote tumor growth and metastasis and inhibit cytotoxic T cells. Yet, macrophages can also kill cancer 
cells after polarization by e.g., lipopolysaccharide (LPS, a bacteria-derived toll-like receptor 4 [TLR4] agonist) 
and interferon gamma (IFNγ). They do so via nitric oxide (NO), generated by inducible NO synthase (iNOS). 
Altering the polarization of macrophages could therefore be a strategy for controlling cancer. Here, we show that 
monophosphoryl lipid A (MPLA, a derivative of LPS) with IFNγ activated macrophages isolated from metastatic 
pleural effusions of breast cancer patients to kill the corresponding patients’ cancer cells in vitro. Importantly, 
intratumoral injection of MPLA with IFNγ not only controlled local tumor growth but also reduced metastasis in 
mouse models of luminal and triple negative breast cancers. Furthermore, intraperitoneal administration of MPLA 
with IFNγ reprogrammed peritoneal macrophages, suppressed metastasis, and enhanced the response to 
chemotherapy in the ID8-p53-/- ovarian carcinoma mouse model. The combined MPLA+IFNγ treatment 
reprogrammed the immunosuppressive microenvironment to be immunostimulatory by recruiting leukocytes, 
stimulating type I interferon signaling, decreasing tumor-associated (CD206+) macrophages, increasing 
tumoricidal (iNOS+) macrophages, and activating cytotoxic T cells through macrophage-secreted interleukin 12 
(IL-12) and tumor necrosis factor α (TNFα). Both macrophages and T cells were critical for the anti-metastatic 
effects of MPLA+IFNγ. MPLA and IFNγ are already used individually in clinical practice, so our strategy to 
engage the anti-tumor immune response, which requires no knowledge of unique tumor antigens, may be ready 
for near-future clinical testing.  
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Introduction 
Cancer elicits an immune response, but solid tumors evade this response, in part by establishing an 
immunosuppressive tumor microenvironment. The tumor microenvironment is composed of tissue-resident cells 
(e.g., fibroblasts and endothelial cells), innate immune cells (e.g., macrophages), and adaptive immune cells (e.g., 
T cells) (1-3). It was discovered over a century ago that intratumoral injection of dead bacteria, named “Coley’s 
toxin” after the physician who devised the treatment, led to durable anti-tumor responses in some patients (4). It 
is likely that the tumor responses were caused by the activation of immune cells, particular macrophages, by 
bacterial components. However, tumor-associated macrophages (TAMs) are usually associated with pro-tumor 
features: TAMs promote tumor growth and metastasis directly (5-7). They also contribute to the tumor 
immunosuppressive microenvironment, allowing tumors to evade the intrinsic anti-tumor immune response, as 
well as T cell-based therapies, including checkpoint blockade (8-10). 
Macrophages can take on a continuum of phenotypes between two major subtypes: classically activated 
and alternatively activated macrophages (11). Classically activated macrophages are stimulated during acute 
inflammation by interferon γ (IFNγ) and toll-like receptor (TLR) ligands, including bacterially derived 
lipopolysaccharide (LPS). These macrophages secrete pro-inflammatory cytokines (tumor necrosis factor α 
[TNFα] and interleukins IL-1β, IL-2, IL-6, IL-12, and IL-23) and metabolize arginine to the “killer” molecule 
nitric oxide (NO) through upregulation of inducible nitric oxide synthase (iNOS). Stimulating macrophages with 
IL-4/IL-13 leads to the alternatively activated macrophage phenotype and the subsequent production of anti-
inflammatory cytokines (IL-10, TGFβ). TAMs usually exhibit traits of the alternatively activated macrophage 
subtype and have been clinically targeted by ablating strategies, such as anti-CSF1R therapeutics, which 
unfortunately have long-term toxicity and high tumor recurrence limiting their use (12-14). However, depending 
on context, macrophages in tumors can also eliminate tumor cells with NO, reactive oxygen species, or by 
phagocytosis, and they can stimulate cytotoxic T lymphocytes to kill tumors by presenting antigens and producing 
pro-inflammatory cytokines (11, 15). Since macrophages exhibit a high degree of plasticity, a better strategy than 
macrophage ablation may be to “reprogram” the TAMs to kill cancer cells and support the elimination of tumors 
.CC-BY-NC-ND 4.0 International licenseavailable under a
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprint (whichthis version posted July 14, 2020. ; https://doi.org/10.1101/2020.07.13.200477doi: bioRxiv preprint 
p. 4 
by cytotoxic T lymphocytes (16, 17). Class IIa histone deacetylase (HDAC) inhibitors can reprogram TAMs to 
anti-tumor macrophages and increase the efficacy of chemotherapy and immunotherapy in preclinical models of 
breast cancer (18). Similarly, selective inactivation of macrophage PI3Kγ promotes an immunostimulatory 
transcriptional program in turn restoring CD8+ T cell activation and cytotoxicity and increasing survival in mouse 
models of head and neck squamous cell carcinoma (19). 
Reprogramming of macrophages and/or direct stimulation of adaptive immunity have been achieved using 
e.g., TLR agonists. TLRs are innate immunity pattern recognition receptors that play fundamental roles in 
activating the innate immune response (20). Nanoparticles loaded with R848 (a TLR7/8 agonist) effectively 
accumulate in TAMs, repolarize them towards an inflammatory phenotype, and show profound tumor-
suppressing effects in a colon cancer mouse model (21). Another delivery approach besides nanoparticles is direct 
intratumoral injection: injection with a CpG oligonucleotide (a TLR9 agonist) reverts resistance to PD-1 blockade 
by expanding multifunctional CD8+ T cells in breast and colon cancer mouse models (22). In a phase I clinical 
study, the combination of motolimod (a TLR8 agonist, subcutaneously administered) with the EGFR inhibitor 
cetuximab (intravenously injected) increased secretion of IL-6, CCL2, and CCL4 and increased natural killer 
(NK) cell circulation and activation (23). Similarly, the TLR7 ligand imiquimod applied as a cream to breast 
cancer skin metastases showed anti-tumor activity and triggered a strong T-helper-1 (Th-1)/cytotoxic immune 
response in responding patients (24, 25). However, the therapeutic efficacy of motolimod and imiquimod is low: 
only two out of eleven squamous cell carcinoma patients and two out of ten breast cancer patients achieved a 
partial response.  
To improve the anti-tumor effects of the TLR agonist, we decided to use a combinatorial approach of the 
TLR4 agonist monophosphoryl lipid A (MPLA) with IFN. MPLA is a derivative of LPS; it can be chemically 
synthesized and displays greatly reduced toxicity while maintaining most of the immunostimulatory activity of 
LPS. The reduced toxicity of MPLA is attributed to the altered signaling downstream of TLR4 activation 
compared to LPS, resulting in decreased induction of inflammatory cytokines (26). MPLA is used as an adjuvant 
in commercially available vaccines against cervical cancer and shingles (27, 28). IFNγ is a cytokine essential for 
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innate and adaptive immunity. It can promote macrophage activation, enhance antigen presentation, coordinate 
lymphocyte-endothelium interaction, regulate Th1/Th2 balance, and control cellular proliferation and apoptosis 
(29, 30). Furthermore, IFNb (a variant of IFN) is approved by the FDA to treat chronic granulomatous disease 
and osteopetrosis (31, 32). Here, we describe how injection of MPLA with IFN provided a collaborative stimulus 
that reprogrammed TAMs to become tumoricidal and activated cytotoxic T cells to elicit not only local tumor 
control but also a systemic immune response to control metastatic breast cancer and ovarian cancer in mice.  
 
Results  
MPLA with IFN reprograms tumor-associated macrophages to tumoricidal macrophages 
To explore strategies to induce the tumoricidal activity of macrophages, we first evaluated whether TAMs, which 
are already polarized to a tumor-promoting phenotype, were plastic enough to be reprogrammed to become 
tumoricidal. TAMs and tumor cells were isolated from the primary tumors of MMTV-PyMT mice (a mouse 
model of luminal B breast cancer) (Fig. S1A, S1B), co-cultured and treated with a TLR agonist (LPS or two TLR 
agonists that have been used clinically: MPLA or polyI:C) alone or in combination with IFN. None of the TLR 
agonists (alone or combined with IFN affected PyMT cancer cell viability in the absence of macrophages (Fig. 
S1C). However, TAMs activated with IFN together with either LPS or MPLA—both TLR4 agonists—killed 
~90% of cancer cells in 48 hours in culture (p<0.001, Fig. 1A, B, Movies S1, S2). In contrast, treating 
macrophages with polyI:C (a TLR3 agonist) combined with IFN, or treatment with LPS, MPLA, polyI:C, or 
IFN alone did not induce the tumoricidal activities of the macrophages (Fig. 1A, B).  
Previously, it had been reported that iNOS is required for the tumoricidal activities of macrophages (33). 
Consistently, only the two combination treatments causing tumoricidal TAM activity—IFN combined with 
either LPS or MPLA—induced iNOS expression (Fig. S1D). Furthermore, inhibition of iNOS activity with L-
NIL blocked the tumoricidal effect of macrophages activated by MPLA combined with IFN (Fig. S1E). Thus, 
TAMs can be reprogrammed to become tumoricidal using IFN combined with either LPS or MPLA, and iNOS 
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activity is required for their tumoricidal effects 
Recently, CD163+ TAMs from the pleural effusions of lung cancer patients were shown to upregulate 
iNOS expression upon in vitro treatment with pseudomonas aeruginosa-mannose-sensitive hemagglutinin (34), 
suggesting that TAMs in patients can be reprogrammed. To formally test this, we isolated macrophages and cancer 
cells from the metastatic pleural effusions of breast cancer patients (Fig. S1F–H) to determine whether human 
TAMs could be activated by MPLA with IFN to kill patient-derived breast cancer cells. Importantly, MPLA 
with IFN was indeed able to reprogram the pleural effusion-derived macrophages, resulting in the killing of 80–
90% of the breast cancer cells isolated from the corresponding patient in vitro (p<0.001, Fig. 1C). To characterize 
the markers associated with the in vitro reprogramming of TAMs to tumoricidal macrophages, we next used RT-
qPCR. We found that MPLA combined with IFN increased the expression of tumoricidal macrophage markers 
(NOS2 [the gene coding for iNOS], CD40, TNF, and IL12B) and reduced the expression of TAM markers (IL10 
and CD206) in the patient-derived macrophages (Fig. 1D). The upregulation of Tnf and Il12b and the 
downregulation of Il10 and CD206 were also shown in primary PyMT tumor-derived macrophages after 
MPLA+IFN treatment (Fig. S1I, S1J). In aggregate, our data show that the TLR4 agonist MPLA combined with 
IFN reprogrammed mouse and human TAMs to tumoricidal macrophages in vitro. 
 
MPLA with IFN suppresses breast tumor growth and lung metastasis  
We next sought to determine whether TLR4 agonists combined with IFN could control cancer cells in vivo, in 
the context of a complex tumor microenvironment. LPS has severe side effects when given in vivo (35), but 
MPLA has been used as adjuvant in vaccines against cervical cancer and shingles (27, 28). We therefore tested 
the effects of intratumoral injection of MPLA with IFN into transplanted MMTV-PyMT (“PyMT” for short, 
luminal B subtype) or 4T1 (triple negative subtype) breast tumors: two models of metastatic breast cancer. We 
applied 1 g MPLA with different doses of IFNto each tumor and compared their inhibitory effects on tumor 
growth to optimize the doses. The growth of PyMT tumors treated with MPLA + 0.33, 1, or 3 g IFN was almost 
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equally suppressed compared to controls (Fig. S2A), and the growth of 4T1 tumors treated with MPLA + 3 or 9 
g IFN was inhibited similarly (Fig. S2B). Thus, we utilized 1 g MPLA with 1 g IFN for the intratumoral 
injection of PyMT tumors, and 1 g MPLA with 3 g IFN for the intratumoral injection of 4T1 tumors.  
This combined MPLA+IFN treatment suppressed primary tumor growth in both models (Fig. 2A, 2C). 
MPLA is a derivative of LPS, which we and others have shown can promote metastasis via activation of 
neutrophils (36, 37), including through the induction of metastasis-promoting neutrophil extracellular traps 
(NETs) (38, 39). However, the treatment did not enhance the levels of NETs in the plasma of PyMT or 4T1 tumor-
bearing mice (Fig. S2C, S2D). Importantly, MPLA with IFN also did not enhance metastasis: rather, the 
treatment significantly inhibited lung metastasis. Microscopy of lung sections showed that all vehicle-treated mice 
had detectable metastasis (Fig. 2B, 2D). In contrast, only two out of five PyMT tumor-bearing mice (Fig. 2B) or 
four out of nine 4T1 tumor-bearing mice (Fig. 2D) had detectable metastases with the MPLA+IFN treatment. 
We therefore speculate that the dose of MPLA used to activate macrophages is too low to lead to the excessive 
NET formation that can drive metastasis. Importantly, the suppressive effect of MPLA with IFN was 
collaborative: IFN alone inhibited breast tumor growth and lung metastasis, but less than the combination 
treatment, and MPLA alone had no effect. The ability to reduce metastasis suggests that local injection into the 
tumor microenvironment can trigger a systemic anti-tumor response. Since intratumoral injection is not the 
standard of care for any cancer type and since not all tumors have a suitable injectable site, we next tested whether 
systemic administration of MPLA with IFN could control tumor growth. We found that intraperitoneal injection 
of MPLA (30 g) with IFN30 g), similar to intratumoral injection, also reduced breast PyMT tumor growth 
(Fig. S2E, S2F), and importantly, there were no obvious toxicities.  
 
MPLA with IFN stimulates chemokine secretion and type I interferon signaling  
To explore how the combination of MPLA with IFN reprograms the tumor microenvironment to control tumor 
growth and metastasis, we focused on the changes induced during the early phases of treatment. We performed 
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cytokine arrays on treated PyMT tumors by collecting tumors 24 hours after the second intratumoral injection 
(Fig. 3A). To measure cytokines, tumors were digested with collagenase/hyaluronidase and centrifuged, and the 
cytokines released to the supernatant were collected. Using this method, we found that MPLA combined with 
IFNinduced the secretion of a large number of chemokines responsible for immune cell recruitment, including 
CCL5 (which recruits leukocytes, including monocytes, to inflammatory sites), CXCL9 (which recruits 
lymphocytes, particularly T cells), CXCL13 (a B lymphocyte chemoattractant), CCL12 (also known as monocyte 
chemotactic protein 5), and CXCL5 (which recruits neutrophils) (Fig. 3B). In addition, we detected increased 
CD40 (a co-stimulatory protein on antigen-presenting cells), IL-12 (which enhances the cytotoxic activity of NK 
cells and CD8+ T lymphocytes), and BAFF (B-cell activating factor) (Fig. 3B). We further confirmed by enzyme-
linked immunosorbent assay (ELISA) the increased secretion of CXCL9 and CCL5 after combined treatment 
with MPLA+IFN (Fig. S3A, S3B). Together, these data indicate that the immune microenvironment was 
dramatically altered by the combined treatment of MPLA with IFNin breast PyMT tumors. 
We next explored the effect of combined MPLA+IFN on gene regulation by analyzing RNA-seq data 
(Fig. 3C). There were only 20 upregulated genes and 5 downregulated genes after treatment with MPLA alone, 
33 upregulated genes and 15 downregulated genes after treatment with IFN alone, but 179 upregulated genes 
and 36 downregulated genes after the combined MPLA+IFNtreatment (Data file S1). Thus, the combined 
treatment was clearly collaborative. Expression of IFN-inducible genes was promoted by IFN alone and by 
MPLA+IFN (Data file S1). In addition, the combination of MPLA with IFN enhanced the expression of type I 
interferon (interferon-α/β)-inducible genes, including Stat1, Stat2, Irgm2, Gbp2, and Cxcl9 (Fig. 3D). These genes 
promote oxidative killing, antimicrobial response, and effector T cell response and stimulate the transcription of 
MHC class II genes, which are critical for the presentation of extracellular pathogens (40-42). MPLA with IFN 
also uniquely decreased the expression of extracellular matrix (ECM)-associated genes (Col3a1, Col4a1, 
Col12a1, and Igfbp3) (Fig. 3D). These genes promote cancer cell growth and migration and can suppress the 
proliferation and cytotoxic activity of T cells (43, 44). The altered transcription of selected type I interferon-
inducible and ECM-associated genes was verified in PyMT tumors by RT-qPCR and was also shown to occur in 
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combination-treated 4T1 tumors by RT-qPCR (Fig. S3C–F). These results indicate that MPLA with IFN 
activated immune cells and also had wider effects on the tumor microenvironment.  
To investigate the functional implications of the altered gene programs, we performed a gene ontology 
(GO) analysis (Fig. 3E). This analysis revealed enhanced immunostimulatory responses, such as type I interferon 
signaling, antigen processing and presentation, and defense response to virus, and showed inhibited 
immunosuppressive responses, such as collagen-activated signaling and ECM organization. Overall, the cytokine 
array data and RNA-seq data demonstrated that MPLA with IFN promoted the expression of genes involved in 
effector immune cell recruitment and stimulated the type I interferon signaling pathway. These results show that 
the combination treatment is necessary to induce the changes in the cytokine environment and gene expression 
that leads to strong anti-tumor responses.  
 
MPLA with IFN reprograms tumor-associated macrophages and activates cytotoxic T cells 
Since the GO analysis revealed that pathways involved in immune responses were specifically upregulated after 
MPLA+IFNtreatment, we next wanted to elucidate the contributions of immune cells to the anti-tumor effects. 
By flow cytometry (Fig. S4), we found that as a percentage, there were almost twice as many immune (CD45+) 
cells had infiltrated into PyMT tumors after intratumoral injection of MPLA+IFN compared to vehicle-treated 
tumors (Fig. S5A). Among the immune cells (S5B-J), the proportion of B cells was decreased (S5F), whereas the 
proportions of CD4 T cells (Fig. S5D) and inflammatory monocytes (Ly6C+Ly6G-, p=0.002, Fig. 4A) were 
increased. The infiltration of macrophages in PyMT tumors (F4/80+, p<0.001, Fig. 4B) was enhanced. Not only 
did the tumors contain more macrophages, but the proportion of macrophages that expressed iNOS (p<0.001, Fig. 
4C) or CD40 (p<0.001, Fig. 4D) was increased, while the proportion of macrophages that expressed CD206 was 
reduced (from 50% to 16%, p<0.001, Fig. 4E), as measured by flow cytometry. Consistently, the numbers of 
iNOS+ or CD40+ cells were also increased by MPLA+IFN as determined by immunofluorescence (IF) staining 
of tumor sections (Fig. 4F, 4G). Together, these results suggest that MPLA with IFN had reprogrammed TAMs 
to tumoricidal macrophages in the mouse breast tumors.  
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We next used a variant of the MMTV-PyMT model, the MMTV-PyMT-chOVA model (45, 46), to 
investigate the effect of the combined treatment on MHC class I antigen-presenting activities. Cancer cells in the 
MMTV-PyMT-chOVA model express the ovalbumin (OVA) peptide SIINFEKL as a model tumor antigen, 
allowing measurement of MHC class I presentation of OVA. In the tumors of these mice, there was an almost 
two-fold increase in the percentage of H-2Kb OVA+ macrophages (p=0.003, Fig. 4H), H-2Kb OVA+ dendritic 
cells (Fig. S5K), and CD103+CD11cHighCD11bHigh cells (Fig. S4, S5L) after MPLA+IFNtreatmentConsistent 
with the increased antigen presentation, the MPLA+IFN treatment significantly increased the infiltration of 
cytotoxic T lymphocytes (CD8a+, p<0.001, Fig. 5A) and the abundance of activated cytotoxic T cells (CD107a+ 
or PD1+) in tumors (Fig. 5B, 5C). Importantly, the combined treatment also promoted the production of effector 
memory T cells (CD44+CD62L-) (p=0.029, Fig. 5D) and enhanced T cell aggregation in the lungs of tumor-
bearing mice (Fig. S5M). Since effector memory cells persist and can provide future protective immunity, 
together, these data provide evidence that MPLA with IFNhas the ability to reverse immune suppression in the 
tumor microenvironment and suggest that the treatment can lead to the activation of lasting adaptive T cell 
immune responses to protect against future metastases.  
 
MPLA with IFN can activate cytotoxic T cells through macrophage-secreted cytokines  
Our in vivo data strongly suggested that MPLA with IFN treatment activated cytotoxic T cells either directly or 
indirectly via macrophages. To test these possibilities, we incubated CD8+ T cells that were isolated from the 
spleens of PyMT tumor-bearing mice with MPLA+IFN in vitro, but found that the combined treatment did not 
directly stimulate T cell activation (Fig. 5E). In contrast, when macrophages derived from the bone marrow of 
the same mice and T cells were co-cultured, MPLA with IFN increased the expression of CD69 on CD8+ T cells 
(p<0.001, Fig. 5E). Together, these results suggest that MPLA with IFN can stimulate cytotoxic T cell functions 
via macrophages. Since we had found that MPLA with IFNpromoted the mRNA expression of two T cell 
activators, IL12B and TNF in breast cancer patient pleural effusion-derived macrophages (Fig. 1D) and primary 
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PyMT tumor-derived macrophages (Fig. S1I) and also enhanced the secretion of IL-12 and CXCL9 in PyMT 
tumors (Figs. 3B, S3A), we explored the possible functions of these three cytokines in the communication 
between macrophages and T cells in vitro by treating with neutralizing antibodies (Fig. 5F). The enhanced 
expression of CD69 was reduced to 54% by treatment with the IL-12 blocking antibody (p=0.001) and to 39% by 
the TNF blocking antibody (p<0.001), indicating that MPLA with IFN activates cytotoxic T cells through the 
macrophage-secreted cytokines IL-12 and TNF. Blocking CXCL9 had no effect on CD69 expression, consistent 
with a likely role in the recruitment rather than the activation of T cells. 
To further determine how MPLA+IFNactivated macrophages affect T cells, we next challenged CD8+ 
T cells isolated from OT1 mice with OVA peptide-incubated macrophages. OT1-derived T cells recognize cells 
with the MHC class I-bound OVA peptide. We found that the OT1 CD8+ T cells were activated by the 
combination of OVA and MPLA+IFNtreated macrophages (p=0.014, Fig. 5G), while MPLA or IFN alone 
had no effect. These results show that MPLA with IFN can activate macrophages to present antigens to cytotoxic 
T cells. Taken together, our in vitro results show that MPLA combined with IFN not only activates macrophages’ 
tumoricidal effects but also enhances their capacity to activate cytotoxic T lymphocytes. 
 
Both macrophages and T cells are essential for the anti-tumor effects of MPLA+IFN  
We next tested which immune cell populations are necessary for MPLA+IFNto eliminate metastatic breast 
cancer. We performed in vivo antibody depletion experiments to target either CD4+ and CD8+cells (through 
combined treatment with anti-CD4 and anti-CD8 antibodies) or macrophages (through treatment with anti-CSF1R 
antibodies). Specific cell depletion was confirmed by flow cytometry of immune cells in tumors (Fig. S6A, S6B). 
In PyMT tumors, T cell depletion reduced the anti-tumor efficacy of MPLA with IFN (Fig. S6C, S6D), but we 
were unable to determine the contribution of macrophages, as anti-CSF1R antibodies was not effective at 
depleting them (Fig. S6A). In 4T1 tumors, depleting either macrophages or T cells was effective (Fig. S6B), and 
the depletion of either cell type abolished the suppressive effects of MPLA+IFN on both tumor growth and lung 
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metastasis (Fig. 6A, 6B). These results suggested that both the innate and adaptive immune system are required 
for the anti-tumor environment elicited by MPLA with IFN.  
Our data suggested that a memory T cell response is activated by MPLA+IFNtreatment (Fig. 5D)To 
test whether a long-lasting immune response was indeed induced, tumor-bearing mice had their tumors surgically 
removed, recovered for two weeks, and were then re-challenged with cancer cells from MMTV-PyMT; ACTB-
ECFP mice (Fig. 6C), allowing us to identify the new cells by their expression of enhanced cyan fluorescent 
protein (ECFP). We found that mice treated with MPLA+IFN had a significantly reduced ECFP+ metastatic 
burden, whereas MPLA or IFNtreated mice had no reduction (Fig. 6D). When T cells were depleted during 
MPLA+IFN treatment (Fig. 6C), the inhibitory impact of MPLA with IFNon metastasis from the new cancer 
cells was abolished (p=0.029, Fig. 6E). These data, together with the enhanced generation of functional memory 
T cells by MPLA with IFN (Fig. 5D), indicate that the combination treatment not only reverses immune 
suppression in the tumors but also triggers anti-tumor memory, which may have a long-lasting effect on 
metastasis. 
 
MPLA with IFNsuppresses metastatic ovarian cancer 
Intraperitoneal MPLA+IFN treatment was successful in our breast cancer model (Fig. S2F). This finding 
motivated us to explore this combination treatment for ovarian cancer, for which intraperitoneal chemotherapeutic 
treatments are used and for which there is a lack of effective treatments for late-stage disease. Furthermore, TAMs 
contribute to immunosuppressive microenvironment in ovarian cancer (47, 48). To determine whether the 
therapeutic benefit of MPLA with IFN might be extended to ovarian cancer, we intraperitoneally injected mice 
with ID8-p53-/- ovarian cancer cells (49), a model that is relevant because Trp53 mutations are found in 94% of 
human high-grade serous ovarian cancer (50). At 7 weeks after ID8-p53-/- cancer cell transplantation (Fig. 7A), 
the tumor-bearing mice were visibly sick (Fig. S7A) and had bloody ascites in their abdominal cavity (Fig. 7B). 
All mice had a higher body weight (Fig. S7B) and many metastases in the peritoneum, pancreas, mesentery, and 
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diaphragm (Table S1). However, when treatment with MPLA+IFN was initiated 3 weeks after cancer cell 
transplantation (Fig. 7A), the mice at the 7-week time point looked healthy (Fig. S7A), and only two out of five 
mice had metastases in the peritoneum (Table S1). Furthermore, MPLA combined with IFN decreased the total 
cell number in the ascites (to just 10% of that found in control mice, p=0.007, Fig. 7C), increased the percentage 
of immune cells in the ascites (CD45+, Fig. S7C), and reduced the proportion of EpCAM+ cancer cells (from 15% 
to 2%, p=0.020, Fig. 7D), indicating that the treatment suppressed the progression of ovarian cancer.  
MPLA with IFN increased the presence of monocytes in the ascites (p=0.008, Fig. 7E), and similar to 
the breast cancer model, the combination treatment altered the balance between the iNOS+ and 
CD206+macrophages (Fig. 7F, 7G): the percentage of iNOS+ macrophages increased from 0.7% to 23% 
(p=0.017), while the percentage of CD206+ macrophages decreased from 92% to 33% (p<0.001). Of note, the 
mouse that had the most metastases in the MPLA+IFN group had the lowest percentage of iNOS+ macrophages 
and the highest percentage of CD206+ macrophages, supporting a direct link between the ability to reprogram 
macrophages and reduce metastasis. Strikingly, MPLA+IFNtreatment prolonged the survival of ID8-p53-/- 
tumor-bearing mice regardless of whether treatment was started at 3 weeks after tumor inoculation (Fig. 7H), or 
six weeks after tumor inoculation, when many mice had small amount of bloody ascites (Fig. 7I).  
Most patients with ovarian cancer will be treated with chemotherapy, but nevertheless the cancer will 
often recur (51). We therefore compared treatment with MPLA+IFN to cisplatin, a widely used chemotherapy 
for ovarian cancer patients. Cisplatin, given weekly for four weeks starting day 17 after tumor cell inoculation, 
and MPLA+IFN, given twice weekly for three weeks starting day 42, increased the median survival of the mice, 
largely to the same extent (Fig. 7I). When MPLA+IFNwas given after four cycles of cisplatin, the median 
survival was increased compared to the monotherapies (Fig. 7I). Thus, MPLA+IFN may offer benefit when 
given after standard of care chemotherapy. Altogether, our data show that MPLA combined with IFN 
dramatically suppresses metastatic breast and ovarian cancers by reversing the tumor immunosuppressive 
microenvironment and stimulating the collaborative innate-adaptive anti-tumor immune response. 
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Breast and ovarian tumors are infiltrated by large numbers of macrophages and T cells. Although these cells can 
kill cancer cells, they must be activated properly. With this study, we developed a strategy for reprogramming the 
immune microenvironment of cancer. We revisited the approach used for Coley’s toxin (dead bacteria) and 
exploited the combined power of the TLR4 agonist MPLA (a derivative of the bacterial component LPS) with 
the cytokine IFN. The combination of MPLA with IFN reversed immune suppression in the tumor 
microenvironment and induced a systemic anti-tumor response. This treatment harnessed the power of 
macrophages and T cells so that these cells together eliminated metastatic breast and ovarian cancer. This result 
is in line with previous reports using other approaches to activate macrophages (18, 19), strongly supporting the 
argument for engaging both innate as well as adaptive immunity to improve the efficacy of cancer 
immunotherapy. Importantly, our strategy for co-stimulating macrophages and T cells did not require knowledge 
of the tumor antigens.  
We found that MPLA with IFN stimulated innate immunity, but in addition, the adaptive immune 
response was critical for the in vivo effects of the treatment. We found that MPLA with IFNdid not stimulate T 
cells directly in vitro and that the activation of CD8+ T cells depended on cytokines secreted by macrophages, 
including IL-12 and TNF. It is likely that MPLA+IFN in vivo also induces dendritic cells to produce IL-12 to 
activate cytotoxic T lymphocyte responses, as such effects have been reported (52). Our data are consistent with 
reports that IL-12 bridges innate and adaptive immunity by enhancing the cytotoxic activity of CD8+ T 
lymphocytes (53) and that intratumor adoptive transfer of tumor-specific CD8+ T cells engineered with transiently 
expressed IL-12 mRNA eradicated tumors in melanoma mouse models (54). TNFcan promote the activation 
and proliferation of naïve and effector T cells (55, 56). Macrophages from murine tumors, as well as from 
malignant pleural effusions of breast cancer patients could be reprogrammed to tumoricidal macrophages by 
MPLA with IFNex vivo. Importantly, this suggest that TAMs in the metastatic tumor microenvironment are 
sufficiently plastic to be reprogrammed to become tumoricidal. Furthermore, the reprogrammed patient-derived 
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macrophages expressed IL12B and TNF, suggesting that a T cell response might also be activated in patients with 
cancer.  
The collaborative therapeutic effect between MPLA and IFN in vivo is likely also related to the fact that 
only the combined treatment induces a type I interferon response in the tumors. Treatment with just IFN, which 
is not a type I interferon, did not induce such a response. Type I interferons play critical roles in anti-cancer 
immunity (reviewed in (57-59)). Important roles include their ability to promote antigen presentation, which is 
consistent with our data showing increased the antigen-presenting activities of macrophages and dendritic cells 
after treatment by MPLA with IFN, but not by either treatment alone. Type I interferons also skew the adaptive 
immune system to promote the development of antigen-specific T cell responses and immunological memory. 
Indeed, we observed that MPLA with IFN significantly increased the abundance of activated cytotoxic T 
lymphocytes and effector memory T cells in tumors. In the tumor re-challenge assay, MPLA+IFNtreated mice 
developed the fewest new metastatic lesions, and T cells were required for this effect, suggesting that the 
combination treatment triggers long-term anti-tumor T cell memory.  
In our experiments, in situ injection of 1 g MPLA (~50 g/kg body weight) with 1–3 g IFN (~50–150 
g/kg body weight) was sufficient to induce local immune modulation in breast tumors and to invoke a systemic 
anti-tumor immune response that protected against metastatic disease, either from spontaneously disseminated 
tumor cells or from cells injected as a re-challenge of the immune system. Potential drawbacks of invoking local 
immune modulation include the reliance on adequate immune infiltrates available for reprogramming and the 
requirement for suitable injectable sites in the tumor. As an alternative, we administrated MPLA with 
IFNintraperitoneally. Although this approach required higher doses (10–30 g, and ~0.5–1.5 mg/kg body 
weight), these are still low compared to other systemically administered antibodies and cytokines.  
MPLA and IFN are already FDA-approved biologics: MPLA as an adjuvant is used in vaccines against 
cervical cancer and shingles, and a variant of IFN (IFN1b) is approved to treat chronic granulomatous disease 
and osteopetrosis. Importantly, we observed no obvious toxicity or induction of metastasis-promoting NETs at 
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the doses that could induce protective immunity in mice, indicating that this combination treatment could be a 
strategy for eliminating tumors without causing severe side effects. We therefore envision that MPLA with IFN 
may be applied as a stand-alone treatment or perhaps used in conjunction with chemotherapeutic agents to prevent 
metastatic recurrence. Metastasis is the leading cause of mortality in cancer patients (60). If the elimination of 
metastasis by MPLA+IFNcan be translated from our preclinical models to patients, then the approach may 
significantly improve the survival rates of late-stage breast and ovarian cancer patients.  
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Materials and Methods 
Study design 
The objective of this research was to develop a new therapeutic strategy to reprogram TAMs to tumoricidal 
macrophages and to reverse the tumor immunosuppressive microenvironment to an immunostimulatory 
microenvironment. We examined the anti-tumor effect of MPLA with IFNby measuring tumor growth and 
metastasis in mouse models of metastatic luminal (PyMT) and triple negative (4T1) breast cancers, as well as in 
an ovarian cancer model (ID8-p53-/-). Importantly, we also investigated the ability of MPLA with IFN to 
reprogram TAMs from the malignant pleural effusions of breast cancer patients. We studied the mechanism of 
the therapy by performing a cytokine array, RNA-seq, and flow cytometry to examine the activation of immune 
cells and by performing neutralization/depletion experiments to explore the requirement for macrophage-secreted 
cytokines and innate-adaptive immunity. In all in vitro experiments, the average results were taken from at least 
three independent experiments or three patients. In all in vivo experiments, the results are representative of at least 
two independent experiments (the numbers of mice and statistical tests are listed in the figure legends). Mice were 
excluded from the study when the breast tumors grew into the abdominal cavity and were randomized before the 
administration of therapy.  
 
Animals 
OT1 mice were purchased from Jackson Laboratory and MMTV-PyMT mice (on C57BL/6 [referred to hereafter 
as BL/6] background) were bred at Cold Spring Harbor Laboratory (CSHL). To obtain MMTV-PyMT; ACTB-
CFP mice, ACTB-ECFP mice (on BL/6 background, originally obtained from Jackson Laboratory) were 
intercrossed with MMTV-PyMT mice. MMTV-PyMT-chOVA mice (46) were a kind gift from Dr. Mathew 
Krummel (University of California, San Francisco). 
Six- to eight-week-old female BL/6 and BALB/c host mice were purchased from Jackson Laboratory and 
acclimated to the animal housing facility for one week prior to performing experiments. All animal experiments 
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were conducted in accordance with procedures approved by the Institutional Animal Care and Use Committee at 
CSHL and the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals.  
 
Patient samples 
Metastatic pleural effusions from three female breast cancer patients were collected during a standard therapeutic 
procedure used to palliate symptoms. Patient 1 was 34 years old and the tumor was estrogen-receptor (ER) 
positive (+), human epidermal growth factor receptor (HER)-2 negative (-); patient 2 was 35 years old and the 
tumor was ER+/HER2+; and patient 3 was 53 years old and the tumor was ER+/HER2-. All research was performed 
in accordance with the New York University and CSHL Institutional Review Board guidelines and regulations, 
and written informed consent was obtained from all patients. 
 
Isolation of macrophages and tumor cells from pleural effusions of breast cancer patients 
Pleural effusions were shipped on ice to CSHL and cells were isolated in less than 24 hours after sample collection 
as follows: the effusions were spun down at 450 x g for 10 minutes to remove the liquid supernatant, and the cell 
pellet was washed with Dulbecco’s Phosphate-Buffered Saline (DPBS) twice, then resuspended in Ammonium-
Chloride-Potassium (ACK) lysis buffer on ice for 5–10 minutes; an additional spin down at 300 x g for 10 minutes 
was performed to eliminate the red blood cells. Then, CD326 (EpCAM) microbeads (#130-061-101, Miltenyi 
Biotec) were applied to enrich for EpCAM+ and EpCAM- cells, according to the manufacturer’s instructions. 
Macrophages were obtained from the EpCAM- cells after 2 hours of adherence to the tissue culture dish and were 
cultured with 50 ng/ml human macrophage colony-stimulating factor (M-CSF, #CYT-308, ProSpec) in RPMI-
1640 (Gibco) containing 20% fetal bovine serum (FBS, Sigma), 200  L-glutamine (#25030081, Gibco), 100 
 sodium pyruvate (#11360070, Gibco), and 50  -mercaptoethanol (#31350010, Gibco). EpCAM+ cells 
were cultured with Dulbecco’s Modified Eagle Medium (DMEM)-F12 (Gibco) containing 20% FBS (Sigma), 
2% B27 (#17504044, Gibco), 20 ng/ml human EGF (#CYT-217, ProSpec), and 4 μg/ml insulin (#12585014, 
Gibco).  
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Isolation and culturing of macrophages and cancer cells from primary breast tumors of mice 
Macrophages and cancer cells for in vitro co-culture assays, Western blot analysis, and MTS assays were isolated 
from the primary tumors of MMTV-PyMT mice (in BL/6 background). The tumors (6–8 mm in diameter) were 
mechanically dissociated and digested with collagenase/hyaluronidase (#07912, STEMCELL Technologies) 
containing DNase I (4 U/ml, #4716728001, Roche) at 37 °C for 45 minutes. After pulse centrifugation (450 x g), 
the supernatant (mostly immune cells) and cell pellets (mostly cancer cells) were collected. CD11b MicroBeads 
(#130-049-601, Miltenyi Biotec) were used to enrich CD11b+ cells from the supernatant, and macrophages were 
obtained by allowing the CD11b+ cells to adhere to the tissue culture dish for 2 hours (non-adherent cells were 
removed by washing with PBS). Cancer cells were isolated from the tumor cell pellets and dissociated into single 
tumor cells with TrypLE Express Enzyme (#12605010, Gibco) containing DNase I at 37 °C for 10 minutes.  
Mouse macrophages were cultured with RPMI-1640 (Gibco) containing 20% FBS (Sigma), 200  L-
glutamine (Gibco), 100  sodium pyruvate (Gibco), 50  -mercaptoethanol (Gibco), and 10 ng/ml mouse 
M-CSF (#CYT-439, ProSpec). Cancer cells were cultured with DMEM + 10% FBS.  
 
In vitro macrophage and tumor cell co-culture assay 
A 24-well glass bottom plate (#P24G-1.5-13-F, MatTek) was coated with fibronectin (1:100, #F1141, Sigma 
Aldrich). Macrophages were seeded (1.5×105/well) to the plate and 2 hours later, stained with CellTracker™ 
Deep Red Dye (1 M, #C34565, Invitrogen). Tumor cells were stained with CellTracker™ Green CMFDA (5-
chloromethylfluorescein diacetate) Dye (1 M, #C7025, Invitrogen) and seeded (5×104/well) to the plate. Two 
hours later, LPS (100 ng/ml, #L4391, Sigma Aldrich), MPLA (a low toxicity derivative of LPS; 100 ng/ml, #tlrl-
mpls, InvivoGen; this product is produced by chemical synthesis and contains 6 fatty acyl groups), polyI:C (1 
g/ml, #tlrl-picw, InvivoGen), mouse IFN (33 ng/ml, #485-MI/CF, R&D Systems), or human IFN (50 ng/ml, 
#285-IF/CF, R&D Systems) was added to the medium, alone or in indicated combinations, and live cell imaging 
was performed with a Yokagawa spinning disk confocal microscope (Solamere Technology Group) and LiveCell 
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Stage Top Incubation System (Pathology Devices). To inhibit iNOS activity, L-NIL (N6-(1-Iminoethyl)-L-lysine 
hydrochloride, 200 M, #1139, TOCRIS) was added to the medium before MPLA with IFN. 
 
RNA extraction and quantitative real-time PCR 
Total RNA from macrophages or primary tumors was extracted using an RNeasy Mini kit (#74104, Qiagen), 
following the manufacturer’s instructions. Reverse transcription was performed with TaqMan™ Reverse 
Transcription Reagents (#N8080234, Invitrogen). Quantitative real-time PCR was performed in a 384-well format 
on a QuantStudio 6-flex Instrument (Applied Biosystems) using PowerUp™ SYBR™ Green Master Mix 
(#A25780, Applied Biosystems). Relative quantitation was performed with the 2(−ΔΔCT) method using -actin 
expression for normalization. The sequences of PCR primers are listed in Table S2.  
 
In vivo tumor experiments 
PyMT cancer cells for orthotopic transplantation were isolated from the primary tumors of MMTV-PyMT mice 
or MMTV-PyMT-chOVA mice (BL/6 background). The cancer cells were isolated as described above and were 
injected immediately into the 4th mammary fat pad of BL/6 mice (2×105 cells/fat pad in 20 μl 1:1 PBS/Matrigel 
[#356231, Corning]) to obtain the transplanted PyMT tumor model. For 4T1 cells, 5×104 cells/fat pad were 
transplanted into the 4th mammary fat pad of BALB/c mice to obtain the 4T1 tumor model. Tumor size was 
measured by caliper, and tumor volume was calculated as volume = (length×width2)/2. Treatment was initiated 
when tumors reached 5–6 mm in size and was given twice a week: 1 g MPLA/tumor (#vac-mpls, InvivoGen) 
and indicated doses of mouse IFN(#485-MI/CF, R&D Systems) were injected into the tumors to optimize the 
doses by comparing their inhibitory effects on tumor growth. Because the growth of PyMT tumors treated with 
MPLA+0.33, 1, or 3 g IFN was almost equally suppressed compared to controls (Fig. S2A) and the growth of 
4T1 tumors treated with MPLA+3 or 9 g IFN was inhibited similarly (Fig. S2B), we chose the following doses: 
1 g MPLA with 1 g IFN (or 1 g MPLA alone or 1 g IFNalone) was used for the intratumoral injection of 
PyMT tumors, and 1 g MPLA with 3 g IFN (or 1 g MPLA alone or 3 g IFNalone) was used for the 
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intratumoral injection of 4T1 tumors. For intraperitoneal administration of PyMT tumors, 30 g MPLA with 30 
g IFNper mouse were used. At the indicated time points, mice were euthanized in a CO2 chamber before 
performing a cardiac perfusion with PBS, and tumors and lungs were removed for analysis. 
For the tumor re-challenge experiments (shown in Fig. 6C), transplanted PyMT tumors were treated with 
MPLA+IFN (intratumoral injection) four times. Two days after the last treatment, breast tumors were surgically 
removed by making a small incision at the skin near the site of the tumor. The tumor along with 4th mammary fat 
pad was excised and the wound was closed using Relfex 7 mm wound clips (#203-1000, CellPoint Scientific). 
Two weeks after tumor removal, ECFP+ PyMT cancer cells were injected into the tail vein of the mice. The 
ECFP+ PyMT cancer cells were isolated from the primary tumors of MMTV-PyMT; ACTB-ECFP mice as 
described above, and 5×105 cells (in 100 μl PBS) were injected into the tail vein of the mice whose tumors had 
been surgically removed. Seventeen days later, the lungs were removed for analysis.  
Ovarian cancer cells ID8-p53-/- were cultured as previously described (49). A total of 5×106 ID8-p53-/- 
cells (in 200 μl PBS) were injected intraperitoneally into BL/6 mice. At indicated times, 10 g MPLA with 20 g 
mouse IFN was administered intraperitoneally to the mice, for six times total. At the end of the experiment (two 
days after last treatment), the mice were weighed and intraperitoneally injected with PBS, and the 
ascites/peritoneal lavage was collected (~12 ml collected per mouse) for cell counting and flow cytometry. 
Ascites/peritoneal lavage was spun down at 300 x g for 10 minutes, and the cell pellet was resuspended in ACK 
lysis buffer on ice for 5–10 minutes, then spun down at 300 x g for an additional 10 minutes to eliminate the red 
blood cells. The total cell numbers were determined by a CellDrop cell counter (DeNovix, Inc.). Cisplatin (10 
g/g body weight, #JM-1550-1000, MBL) was administrated intraperitoneally to the mice every week, for a total 
of four times. MPLA (10 g) with mouse IFN20 g) was administered as indicated. Mice were euthanized 
when the presence of ascites was evident and affected the mobility of the mouse. 
 
Lung metastasis analysis 
Lungs were placed in PBS in a vacuum desiccator for 2 hours, then fixed in 4% paraformaldehyde (PFA) for 4 
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hours, infiltrated with 30% sucrose in PBS for 48 hours, and embedded in OCT compound. The blocks were then 
placed in a custom-made cutting chamber with razor blade inserts every 2 mm, and the block was cut into 2 mm 
sections. These sectioned lung pieces were then re-embedded in fresh OCT and sent to the Histology Core at 
CSHL for cross-sectional cuts from the entire lung tissue and hematoxylin and eosin (H&E) staining. The 
metastatic burden was calculated as the percentage of metastasis/lung area, determined using Aperio eSlide 
Capture Devices software (Leica Biosystems).  
 
Cytokine array 
Twenty-four hours after the second intratumoral injection, transplanted PyMT tumors were collected, weighed, 
and digested with collagenase/hyaluronidase (25 mg tumor/1 ml enzyme) containing DNase I at 37 °C for 30–45 
minutes. The supernatant that contained secreted cytokines was collected and spun down to remove cells and cell 
debris (12,000 x g, 30 minutes). Supernatant samples (1 ml) and a Proteome Profiler Mouse XL Cytokine Array 
Kit (#ARY028, R&D Systems) were used according to the manufacturer’s instructions. Films were scanned, and 




Twenty-four hours after the second intratumoral injection, transplanted PyMT tumors were collected and total 
RNA was extracted using an RNeasy Mini Kit (#74104, Qiagen). RNA-seq libraries were prepared using a TruSeq 
Stranded mRNA Library Prep Kit (#20020594, Illumina) and sequenced using a NextSeq500 High Output 
Illumina platform with 76 base single end reads at the CSHL Next Generation Sequencing Core Facility, which 
yielded an average of 33.3 million filtered reads per sample. FASTQ sequencing files were processed and 
analyzed using the Galaxy server hosted by the CSHL Bioinformatics Core Facility. Reads were aligned to the 
GRCm38/mm10 reference mouse genome. Gene read counts were determined using featureCounts (61). 
Differential gene expression analysis was performed using DESeq2, with a 0.1 false discovery rate (FDR)-
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adjusted p-value cutoff for significance. DESeq2-normalized read counts of the top genes that were uniquely 
changed in the MPLA+IFN group were visualized as a heatmap using http://www2.heatmapper.ca/expression/. 
Genes that were uniquely upregulated or downregulated in the MPLA+IFN group were used as the input for 
biological process gene ontology analysis (http://geneontology.org/). 
 
Flow cytometry 
Two days after the last (6th) intratumoral injection, tumors were harvested and processed as previously described 
(45). Briefly, tumors were mechanically dissociated and digested with collagenase/hyaluronidase containing 
DNase I at 37 °C for 30–45 minutes, lysed with ACK lysis buffer, and filtered with 40 m cell strainer. For flow 
cytometry staining, cells (1×106) were incubated with mouse Fc receptor blocker (#NB309, Innovex) at 4 °C for 
10 minutes, then stained with the appropriate antibodies to surface markers at 4 °C for 30 minutes in the dark, 
and/or fixed/permeabilized (Cytofix/Cytoperm™ Fixation/Permeabilization Kit, #554714, BD Biosciences) and 
stained with intracellular antibodies at 4 °C for 30 minutes. A Zombie Aqua Fixable Viability Kit (#423101, 
BioLegend) was used to differentiate dead and live cells. The stained populations were analyzed using a Fortessa 
flow cytometer (BD Biosciences) and FlowJo software (BD Biosciences). The following antibodies were from 
BioLegend: anti-mouse CD45-BV785 (#103149), CD3-Alexa Fluor 647 (#100209), CD3-APC/Cy7 (#100221), 
CD11b-APC (#101212), CD4-FITC (#100510), CD8a-PE (#100708), CD8a-APC/Cy7 (#100714), CD19-PE/Cy5 
(#115509), CD11c-PE/Cy7 (#117318), CD11c-APC/Cy7 (#117324), Ly6C-APC/Cy7 (#128026), Ly6G-FITC 
(#127605), F4/80-PerCP/Cy5.5 (#123127), F4/80-Alexa Fluor 488 (#123120), F4/80-BV605 (#123133), CD40-
PE/Cy7 (#124621), CD206-FITC (#141704), CD69-FITC (#104505), CD107a-PE (#121612), PD1-FITC 
(#135213), CD44-PerCP/Cy5.5 (#103032), CD62L-APC (#104412), H-2KbOVA-APC (#141605), anti-human 
EpCAM-Alexa Fluor 647 (#324212), CD45-BV510 (#368525), and CD68-APC (#333810). The other antibodies 
were: CD11b-PE (#557397, BD Biosciences), CD335-eFluor 450 (#48335180, Invitrogen), iNOS-PE 
(#12592082, Invitrogen), and CD103-FITC (#11103182, Invitrogen). 
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Immunofluorescence staining 
Tumors were fixed in 4% PFA, infiltrated with 30% sucrose in PBS, and embedded in OCT compound. The lungs 
were processed as above. Frozen tissues were cryosectioned at the Histology Core at CSHL. OCT compound-
embedded tissue sections were post-fixed with ice-cold methanol and acetone (1:1 ratio), rinsed with PBS, 
blocked with Fc receptor blocker (#NB309, Innovex), and incubated with 1 × blocking buffer (5% goat serum 
[#X0907, Dako], 2.5% BSA, 0.1% Triton X-100 in PBS) (38). Tumor sections were then incubated with 
fluorochrome-conjugated antibody (1:100, Alexa Fluor 488 anti-mouse F4/80, #123120, BioLegend; or PE anti-
mouse CD40, #124610, BioLegend; or PE anti-iNOS, #12592082, Invitrogen; or FITC anti-mouse CD8a, 
#100706, BioLegend) in 0.5 × blocking buffer overnight at 4 °C. Lung sections were incubated with anti-PyMT 
antigen antibody (1:100, #ab15085, Abcam) overnight. The second day, tissue sections were counterstained with 
DAPI and mounted with mounting media (#17985-16, Electron Microscopy Sciences), while lung sections were 
incubated with Alexa Fluor 488 goat anti-Rat secondary antibody (1:1500, #A11006, Invitrogen) for 45 minutes, 
then incubated with Alexa Fluor 647 anti-mouse CD4 (1:100, #100424, BioLegend) and PE anti-mouse CD8a 
(1:100, #100708, BioLegend) overnight. The third day, lung sections were counterstained with DAPI and 
mounted with mounting media. Images were obtained with a Leica SP8 confocal microscope. The positive area 
of F4/80, CD8a, CD40, or iNOS in tumor sections was analyzed with ImageJ. 
For the tumor re-challenge assay, lung sections were stained with anti-ECFP antibody (1:100, #AHP2986, 
Bio-Rad) and Alexa Fluor 488 goat anti-rabbit secondary antibody (1:1500, #A11070, Invitrogen). Images were 
scanned using an Aperio ScanScope® FL System (Leica Biosystems), and ECFP+ lung metastasis was determined 
using Aperio eSlide Capture Devices software (Leica Biosystems).  
 
In vitro T cell activation experiments  
CD8+ T cells were isolated from the spleens of transplanted PyMT tumor-bearing mice with a CD8a+ T Cell 
Isolation Kit (#130-104-075, Miltenyi Biotec), according to the manufacturer’s instructions. Macrophages were 
differentiated from the bone marrow of these mice. The bone marrow was cultured for six days with 10 ng/ml 
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mouse M-CSF (#CYT-439, ProSpec) on Not TC-treated culture dishes (#430597, Corning). The attached cells at 
the end of this culture period are unpolarized macrophages (62). CD8+ T cells were cultured with or without 
macrophages under different experimental conditions, as indicated below and in the figure legends, in RPMI-
1640 with 20% FBS, 200  L-glutamine, 100  sodium pyruvate, and 50  -mercaptoethanol (all of these 
reagents in the T cell culture medium were from Gibco). Macrophages were seeded 2 hours before T cells to 
allow for their attachment, and MPLA (100 ng/ml, #tlrl-mpls, InvivoGen), mouse IFN(33 ng/ml, #485-MI/CF, 
R&D Systems), or the two together were added to the culture system immediately after the seeding of T cells. 
The activation of T cells was identified by CD69 expression using flow cytometry, similar to the experiments 
described above using cells isolated from tumors. To block the cytokines that activate CD8+ T cells, neutralizing 
antibodies against IL-12 (1 g/ml, #AF-419-NA, R&D Systems), TNF5 g/ml, R&D Systems 
or CXCL9 (6 g/ml, #AF-492-NA, R&D Systems) were added to the co-culture system 30 minutes before MPLA 
with IFN 
For the antigen-presenting assay, CD8+ T cells were isolated from the spleens of OT1 mice (Jackson 
Laboratory) with a CD8a+ T Cell Isolation Kit (#130-104-075, Miltenyi Biotec). Macrophages were derived from 
the bone marrow of PyMT tumor-bearing mice as above and treated with MPLA (100 ng/ml, #tlrl-mpls, 
InvivoGen), IFN(33 ng/ml, #485-MI/CF, R&D Systems), or the two together for 16 hours, then incubated with 
OVA-Q4H7 peptide (10-9 M, #AS-64405, AnaSpec) for 2 hours. The pre-treated macrophages were washed with 
PBS and finally added to CD8+ T cells. CD69 expression of CD8+ T cells was identified by flow cytometry. 
 
Immune cell depletion/neutralization experiments 
Anti-CD8 (#BE0004-1, BioXCell) and anti-CD4 (#BE0003-1) antibodies, or anti-CSF1R (#BE0213) antibody, 
were injected intraperitoneally one day before treatment with MPLA+IFN. For the first depletion, 0.5 mg of anti-
CD4 and 0.5 mg of anti-CD8, or 1 mg of anti-CSF1R were injected per mouse. For the subsequent depletions, 
0.2 mg of anti-CD4 and 0.2 mg of anti-CD8, or 0.5 mg of anti-CSF1R were injected per mouse.  
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Statistics 
Prism software (version 8.4.1, GraphPad) was used to analyze the data. In survival experiments, Kaplan-Meier 
survival curves were plotted and log rank test was performed. In all other experiments with only two groups, the 
unpaired t-test (equal variances) or unpaired Welch t-test (unequal variances) was used. One-way ANOVA (with 
equal variances) or Welch’s ANOVA (unequal variances) was performed for experiments with more than two 
groups. Bartlett’s test or Brown-Forsythe test was used to assess equality of variances among groups. When the 
ANOVA was significant, group means were compared as indicated in the figures and p-values adjusted for 
multiple comparisons were obtained using the Holm-Sidak procedure (equal variances) or Dunnett T3 procedure 
(unequal variances). All graphs present the mean, the error bars represent the standard deviation (s.d.), and p-
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Fig. 1. MPLA with IFN induces tumoricidal effects of breast tumor-associated macrophages (TAMs) from 
mice and patients. (A) Macrophages and PyMT tumor cells were isolated from the primary tumors of MMTV-
PyMT (BL/6) mice and co-cultured for 48 hours in the presence or absence of the indicated treatments. Graph 
depicts the average results of three independent experiments. (B) Statistic analysis of relative PyMT cancer cell 
numbers for panel A. (C) Macrophages and EpCAM+ cancer cells were isolated from pleural effusions of breast 
cancer patients and co-cultured under indicated conditions. EpCAM+ cancer cells did not proliferate during co-
culture. Graph depicts the average results from three patients. For both A and C, macrophages were stained with 
CellTracker™ Deep Red Dye, while tumor cells were stained with CellTracker™ CMFDA Dye. Deep Red dye 
is falsely colored green for clarity. LPS (100 ng/ml), MPLA (100 ng/ml, low-toxicity derivative of LPS; the form 
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we used was produced by chemical synthesis and contains 6 fatty acyl groups), polyI:C (1 g/ml), mouse IFN(33 
ng/ml), or human IFN(50 ng/ml) was added at 0 hour. (D) Expression of genes in pleural effusion-derived 
macrophages was determined by RT-qPCR 24 hours after indicated treatments were initiated. Graph depicts the 
average results from three patients. NOS2, CD40, TNF, and IL12B (p40 subunit of IL-12) are markers of 
tumoricidal macrophages. IL10 and CD206 are markers of TAMs. The relative expression to ACTB was 
normalized to vehicle, which was set to 1. One-way ANOVA was performed for all panels and mean with standard 
deviation error bars (mean±s.d.) was presented for each experimental group. 
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Fig. 2. Intratumoral administration of MPLA with IFN suppresses breast tumor growth and lung 
metastasis in mice. (A) Tumor growth curve of transplanted PyMT tumors. A total of 2×105 cancer cells isolated 
from the primary tumors of MMTV-PyMT mice were orthotopically injected into the 4th mammary fat pad of 
BL/6 mice to obtain PyMT tumors. Arrows indicate time of treatments (twice per week); 1 g MPLA, 1 g mouse 
IFN, or the two together were used per tumor. N=8 tumors per group. (B) Lung metastatic burden of PyMT 
tumor-bearing mice was determined by H&E staining. Lung tissues were collected three days after last treatment. 
N=4–6 mice per group. (C) Tumor growth curve for 4T1 tumors: 5×104 4T1 tumor cells were transplanted into 
the 4th mammary fat pad of BALB/c mice to obtain 4T1 tumors. Arrows indicate time of treatments (twice per 
week); 1 g MPLA, 3 g mouse IFN, or the two together were used per tumor. N=8 tumors per group. (D) Lung 
metastatic burden of 4T1 tumor-bearing mice as determined by H&E staining. Lung tissues were collected three 
days after last treatment. N=5–9 mice per group. Graphs are representative of at least two independent 
experiments. One-way ANOVA was performed for the tumor volume analysis at the end time point and for the 
lung metastasis analysis (mean±s.d.), and because the s.d. was significantly different between the groups (unequal 
group variances), Welch’s ANOVA was used for Fig. 2A, 2B, and 2D. *** p<0.001, compared to vehicle. 
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Fig. 3. MPLA with IFN enhances secretion of chemokines and stimulates the type I interferon signaling 
pathway in PyMT tumors. (A) Experimental design for obtaining cytokine array and RNA-seq data; 1 g 
MPLA, 1 g mouse IFN, or the two together were used per PyMT tumor. The treated tumors were collected 24 
hours after the second intratumoral injection. (B) Heatmap of the secreted cytokines that were changed by the 
combination treatment (MPLA+INF) compared to vehicle. (C) Venn diagrams of upregulated and 
downregulated genes in tumors after the indicated treatments. (D) Heatmap of the top genes that were uniquely 
changed in the MPLA+INFtreatment group compared to the vehicle group. (E) Gene ontology analysis of the 
genes that were up- or down-regulated in the MPLA+INFgroup. *FDR<0.05, **FDR<0.01, ***FDR<0.001, 
****FDR<0.0001, compared to vehicle. 
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Fig. 4. MPLA with IFN reprograms TAMs to be tumoricidal in breast tumors. (A) Flow cytometry of 
inflammatory monocytes in PyMT tumors after the last (6th) intratumoral injection of the indicated agents. N=5 
mice per group. (B) IF staining of macrophages (F4/80+) in PyMT tumors. In total, 6–14 field of views (FOVs) 
were evaluated from four mice per group. Scale bar: 50 m. (C–E) The percentage of tumoricidal macrophages 
(iNOS+ or CD40+) and TAMs (CD206+) of total macrophages were identified by flow cytometry. N=3–6 mice 
per group. (F, G) IF staining of iNOS+ (F) and CD40+ cells (G) in breast PyMT tumors. In total, 6–14 FOVs were 
evaluated from four mice per group. Scale bar: 50 m. (H) Antigen-presenting activities of macrophages were 
determined by the percentage of H2-Kb OVA+ cells in PyMT-chOVA tumors: 2×105 cancer cells isolated from 
primary tumors of MMTV-PyMT-chOVA mice were transplanted into BL/6 mice to obtain tumors. N=5 mice 
per group. For all figure panels, the analysis was performed two days after the last (6th) intratumoral injection. 
Graphs are representative of at least two independent experiments. One-way ANOVA was performed for all 
panels (mean±s.d.), and due to unequal group variances, Welch’s ANOVA was used for Fig. 4B, 4F and 4G.  
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Fig. 5. MPLA with IFN can activate cytotoxic T cells through macrophage-secreted IL-12 and TNF. (A) 
IF staining of CD8+ T cells in breast PyMT tumors. In total, 5–9 FOVs were evaluated from four mice per group. 
Scale bar: 50 m. (B–D) The percentages of cytotoxic T cells (CD8+CD107a+, B), PD1+CD8+ T cells (C), and 
effector memory CD8+ T cells (CD44+CD62L-, D) in breast PyMT tumors were identified by flow cytometry. 
For panels A–D, the analysis was performed two days after the last (6th) intratumoral injection. (E–G) CD69 
expression of CD8+ T cells in in vitro co-culture systems was identified by flow cytometry. (E) CD8+ T cells 
isolated from the spleens of PyMT tumor-bearing mice were cultured with or without macrophages derived from 
the bone marrow of the same mice, and MPLA (100 ng/ml) (or mouse IFN[33 ng/ml] or a combination of the 
two) was added to the cell cultures immediately after the seeding of T cells. (F) CD8+ T cells were cultured with 
macrophages similarly to (E), and the neutralized antibodies of IL-12, TNF, or CXCL9 were added to co-
cultures 30 minutes before adding MPLA with IFN. (G) MPLA with IFN promotes the antigen-presenting 
activity of macrophages to CD8+ T cells. Macrophages derived from the bone marrow of PyMT tumor-bearing 
mice were activated with MPLA (or IFN or a combination of the two) for 16 hours, then incubated with OVA-
Q4H7 peptide (10-9 M) for 2 hours. The pretreated macrophages were washed with PBS and added to the CD8+ 
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T cells that had been isolated from the spleens of OT1 mice. One-way ANOVA was performed for all panels 
(mean±s.d.), and due to unequal group variances, Welch’s ANONA was used for Fig. 5A, 5B, 5D, and 5G.  
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Fig. 6. Both the innate and adaptive immune systems are required for the anti-tumor response to MPLA 
with IFN. (A) Tumor growth curve of 4T1 tumors after T cell depletion (anti-CD4/CD8) or macrophage 
depletion (anti-CSF1R). N=8 tumors per group. Immune cell depletion was performed one day before 
intratumoral injection of MPLA with IFN. One-way ANOVA was performed for the tumor volume analysis at 
the end time point. ***p<0.001 compared to MPLA+IFN+IgG. (B) Lung metastatic burden of 4T1 tumor-
bearing mice was determined by H&E staining. Lung tissues were collected three days after last MPLA+IFN 
treatment. N=9 mice per group. (C) Procedure of tumor re-challenge assay with or without T cell depletion. i.t.: 
intratumoral administration; i.v.: intravenous. (D–E) Lung metastasis formed by newly injected breast cancer 
cells (ECFP+) without (D) or with (E) T cell depletion was determined by IF staining of lung sections for ECFP. 
ECFP+ cancer cells were isolated from the primary tumors of MMTV-PyMT; ACTB-ECFP mice. N=4–5 mice 
per group. One-way ANOVA was performed for all lung metastasis analyses (mean±s.d.), and due to unequal 
group variances, Welch’s ANONA was used for Fig. 6B, 6D, and 6E. 
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Fig. 7. MPLA with IFNsuppresses metastatic ovarian cancer in mice. (A) Experimental design. A total of 
5×106 ID8-p53-/- ovarian cancer cells were injected intraperitoneally into C57BL/6 mice. Three weeks later, 10 
g MPLA with 20 g mouse IFN was applied to the mice every five days, for a total of 6 times. Two days after 
the last treatment (~7 weeks after transplantation), tumor-bearing mice were euthanized and ascites/peritoneal 
lavage was collected for flow cytometry. i.p.: intraperitoneal administration. (B) Metastasis was evident from the 
appearance of the ascites/peritoneal lavage of the treated mice. (C, D) Metastasis was determined by the total cell 
number (C) and percentage of epithelial cancer cells (EpCAM+, D) in the ascites/peritoneal lavage. (E–G) The 
proportions of monocytes (Ly6C+Ly6G-, E), of tumoricidal macrophages (iNOS+, F), and of TAMs (CD206+, G) 
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in ascites/peritoneal lavage were determined by flow cytometry. N=5 mice per group. Graphs are representative 
of at least two independent experiments. Unpaired t-test was performed (mean±s.d.), and due to unequal group 
variances, Welch’s t-test was used for Fig. 7C, 7D, and 7F. (H) Kaplan-Meier survival curves of ID8-p53-/- tumor-
bearing mice treated with MPLA+IFN every five days. N=10 mice per group. Log-rank test was used: p<0.0001. 
(I) Kaplan-Meier survival curves of ID8-p53-/- tumor-bearing mice treated with MPLA+IFN alone or in 
combination with cisplatin (10 g/g body weight) administered as indicated (N=5 mice per group. Log-rank test 
was used: p<0.0001. Median survival times: Vehicle: 63 days; MPLA+IFNdays; cisplatin: 116 days; and 
cisplatin followed by MPLA+ IFNundefined at 150 days. 
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